Coronavirus vaccine update: Serum Institute of India says will resume trials after DCGI nod
Pharma giant AstraZeneca on Saturday said that clinical trials for the AstraZeneca Oxford coronavirus vaccine have resumed in the UK
September 13, 2020 / 02:19 PM IST
4 | Chinese President Xi Jinping offers to cooperate with India, BRICS countries to develop COVID-19 vaccine: Chinese President Xi Jinping on November 17 offered to cooperate with India and other BRICS nations in the development of vaccines against the coronavirus and called for holding a symposium by the five-member bloc on traditional medicine to explore its role in the COVID-19 prevention and treatment.
Serum Institute of India (SII) will resume clinical trials of AstraZeneca's COVID-19 vaccine candidate after getting the permission from the Drugs Controller General of India (DCGI), the Pune-based vaccine maker said on September 12.
Pharma giant AstraZeneca on Saturday said that clinical trials for the AstraZeneca Oxford coronavirus vaccine, AZD1222, have resumed in the UK following confirmation by the Medicines Health Regulatory Authority (MHRA) that the trials were safe.
"Once DCGI will give us the permission to restart the trials in India, we will resume the trials," SII said in a statement.
Follow our LIVE Updates on the coronavirus pandemic here
In a tweet, SII CEO Adar Poonawalla said: "As I'd mentioned earlier, we should not jump to conclusions until the trials are fully concluded. The recent chain of events is a clear example why we should not bias the process and should respect the process till the end. Good news, @UniofOxford."
The human trials resumed days after a pause had been announced in the trials after an adverse reaction in one of the participants.
Following the suspension, the DCGI directed Serum Institute of India to suspend till further orders new recruitment in phase 2 and 3 clinical trials of the vaccine candidate.
AstraZeneca and the University of Oxford, as the trial sponsor, on Saturday said that they cannot disclose further medical information but confirmed that independent investigations concluded that the trials were safe to restart.Follow our full COVID-19 coverage here